FOXP1
FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 5 more.
Overview
Transcriptional repressor. Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential. Plays an important role in the specification and differentiation of lung epithelium.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.67, somatic mutation 0.86). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 5 more.
- 1 · What it is
FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 5 more.
- 2 · What goes wrong in cancer
Transcriptional repressor. Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential.
- 3 · How drugs use it
No product in this corpus aims at FOXP1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:3823 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9H334 (protein name, function text, keywords and locations (REST API)); CIViC gene FOXP1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000114861 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: gastric cancer 0.52, oesophageal cancer 0.51, prostate cancer 0.56, ovarian cancer 0.51, melanoma 0.64, neuroendocrine neoplasm 0.52 (GraphQL API, CC0)); IntOGen FOXP1 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional repressor. Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential. Plays an important role in the specification and differentiation of lung epithelium. Acts cooperatively with FOXP4 to regulate lung secretory epithelial cell fate and regeneration by restricting the goblet cell lineage program; the function may involve regulation of AGR2. Essential transcriptional regulator of B-cell development. Involved in regulation of cardiac muscle cell proliferation. Location: Nucleus (UniProt). Locus 3p13 (HGNC).
- Skin cancer: Open Targets association 0.68 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.66 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Prostate cancer: Open Targets association 0.56 with prostate cancer (MONDO_0008315); IntOGen driver in 1 cohort (PRAD)
- Neuroendocrine tumours: Open Targets association 0.52 with neuroendocrine neoplasm (MONDO_0019496)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.52 with gastric cancer (MONDO_0001056)
- Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FOXP1" OR ABSTRACT:"FOXP1" OR TITLE:"forkhead box P1" OR ABSTRACT:"forkhead box P1" OR TITLE:"Forkhead box protein P1" OR ABSTRACT:"Forkhead box protein P1" OR TITLE:"QRF1" OR ABSTRACT:"QRF1" OR TITLE:"12CC4" OR ABSTRACT:"12CC4" OR TITLE:"HSPC215" OR ABSTRACT:"HSPC215") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FOXP1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetMAP2K4
Shares Biliary tract cancer (all types), Skin cancer (all types), Oesophageal cancer, Breast cancer (all types).
- TargetARID2
Shares Biliary tract cancer (all types), Skin cancer (all types), Oesophageal cancer, CIViC.
- TargetPALB2
Shares Biliary tract cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetCDH11
Shares Biliary tract cancer (all types), Skin cancer (all types), Oesophageal cancer, Breast cancer (all types).
- TargetPBRM1
Shares Biliary tract cancer (all types), Skin cancer (all types), Oesophageal cancer, CIViC.
- TargetFGFR4
Shares Biliary tract cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetBAP1
Shares Biliary tract cancer (all types), Oesophageal cancer, Breast cancer (all types), CIViC.
- TargetSMAD4
Shares Biliary tract cancer (all types), Oesophageal cancer, Breast cancer (all types), CIViC.